Breast Cancer

Kisqali® Improves Outcomes of Premenopausal Women with HR+/HER2- Advanced Breast Cancer (12-12-2017)

It was announced today that results from the Phase III MONALEESA-7 trial evaluating Kisqali® (ribociclib) in combination endocrine-based therapy in premenopausal or perimenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2... Continue Reading

Keytruda Immunotherapy Shows Promise for Patients With Herceptin-resistant Breast Cancer (12-12-2017)

A combination of Keytruda (pembrolizumab) and Herceptin (trastuzumab), tested in patients with Herceptin-resistant advanced HER2-positive breast cancer, was well tolerated and had clinical benefit in patients whose tumors were positive for a biomarker... Continue Reading

Kisqali® Improves Outcomes for Premenopausal Women with HR+/HER2- Advanced Breast Cancer (11-14-2017)

Premenopausal breast cancer is a biologically distinct and more aggressive disease than postmenopausal breast cancer and is the leading cause of cancer death in women 20-59 years old.1,2 ,3 Historically there younger women were treated the same as their... Continue Reading

Nerlynx Modestly Improves Survival of HER 2-Positive Early Stage Breast Cancer (11-1-2017)

Positive results from the clinical trial evaluating neratinib for the extended adjuvant treatment of early stage HER2-positive breast cancer following trastuzumab-based therapy (ExteNET trial) were presented at the European Society of Medical Oncology... Continue Reading

Verzenio Demonstrates Superior Progression-Free Survival in Advanced Breast Cancer (10-30-2017)

Recently released clinical trial results from the Phase 3 MONARCH 2 study showed that Verzenio (abemaciclib), a cyclin-dependent kinase (CDK) 4 & 6 inhibitor, when administered in combination with fulvestrant, significantly improves the time to cancer... Continue Reading

Radius Health Receives FDA Fast Track Designation for Elacestrant (10-26-2017)

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for elacestrant, an investigational oral selective estrogen receptor down-regulator/degrader (SERD) as a treatment of women with ER+ and HER2- advanced or metastatic breast... Continue Reading

Immunotherapy Active Against Triple-Negative Breast Cancer (10-12-2017)

October is breast cancer awareness month and patients with triple-negative breast cancer (TNBC) should be aware that data from two clinical trials provide additional evidence that they may derive benefit from checkpoint inhibitor therapy.1-4 About Triple... Continue Reading

LynparzaTM Slows Spread of Inherited Breast Cancer Caused By BRCA Mutations (10-10-2017)

LynparzaTM (olaparib), a new drug treatment for women with advanced ovarian cancer associated with defective BRCA genes also appears to slowe the progression of breast cancer caused in part by mutations in the BRCA gene.  BRCA is an inherited condition... Continue Reading

FDA approves new treatment for certain advanced or metastatic breast cancers (10-5-2017)

The U.S. Food and Drug Administration today approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed... Continue Reading

Annual Mammography Starting at Age 40 Prevents the Most Cancer Deaths (09-13-2017)

When to initiate screening for breast cancer, how often to screen, and how long to screen are questions that continue to spark emotional debates. A new study compares the number of deaths that might be prevented as a result of three of the most widely... Continue Reading

« Previous PageNext Page »